Standard Biotools (LAB) Asset Writedowns and Impairment (2011 - 2026)

Standard Biotools (LAB) has reported Asset Writedowns and Impairment for 9 consecutive years, with $1.1 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Asset Writedowns and Impairment rose 97.06% year-over-year to $1.1 million in Q2 2026; TTM through Jun 2026 was $3.9 million, a 94.58% increase from a year earlier, with the FY2025 full-year figure at $3.5 million, up 37.4% from the prior year.
• Asset Writedowns and Impairment was $1.1 million for Q2 2026 at Standard Biotools, up from $696000.0 in the prior quarter.
• Over five years, Asset Writedowns and Impairment peaked at $3.5 million in Q2 2022 and troughed at $100000.0 in Q3 2024.
• A 5-year average of $937277.8 and a median of $678500.0 in 2022 frame the typical range for Asset Writedowns and Impairment.
• Across the five-year window, Asset Writedowns and Impairment plunged 94.29% in 2023 and surged 515.0% in 2025, its largest moves.
• Over 5 years, Asset Writedowns and Impairment stood at $661000.0 in 2022, then retreated by 24.96% to $496000.0 in 2023, then rose by 7.46% to $533000.0 in 2024, then surged by 180.11% to $1.5 million in 2025, then decreased by 28.06% to $1.1 million in 2026.
• The last three Asset Writedowns and Impairment figures came in at $1.1 million (Q2 2026), $696000.0 (Q1 2026), and $1.5 million (Q4 2025), per Business Quant data.